Allogeneic T Cell Therapies Market Report 2026

Allogeneic T Cell Therapies Market Overview

• Allogeneic T Cell Therapies market size has reached to $1.26 billion in 2025 • Expected to grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Increasing Cancer Cases Drive Demand For Innovative Therapies • Market Trend: Innovative Solutions Enhanced Allogeneic T Cell Therapies Market Growth • North America was the largest region in 2025.

What Is Covered Under Allogeneic T Cell Therapies Market?

Allogeneic T cell therapies are a type of medical treatment where T cells, a crucial component of the immune system, are obtained from a donor (rather than the patient) and used to target and destroy cancer cells in the recipient. Allogeneic T-cell therapies are primarily used in the treatment of various cancers, particularly those that are difficult to treat with conventional methods. The main types of allogeneic T cell therapies are chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. Chimeric antigen receptor (CAR) T-cell therapies are a type of immunotherapy where a patient's T-cells are genetically modified to target and destroy cancer cells. This treatment involves reprogramming T-cells to recognize specific proteins in cancer cells. The antigen types for these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, and others. These therapies are used for therapeutic indications such as cancer, autoimmune diseases, infectious diseases, and more, and are utilized by end users including hospitals, specialty clinics, research institutes, and others.

What Is The Allogeneic T Cell Therapies Market Growth Forecast?

The allogeneic t cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to demand for cost-effective cell therapies, expansion of oncology pipelines, improvements in donor matching, regulatory support for cell therapies, growth in specialty cancer centers. Major trends in the forecast period include shift toward off-the-shelf cell therapies, rising clinical trials in oncology, growing focus on scalable cell manufacturing, increased investment in cell engineering, expansion of specialized treatment centers.

Global Allogeneic T Cell Therapies Market Segmentation

1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies 2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types 3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Other Therapeutics Indications 4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies 2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies

What Is The Driver Of The Allogeneic T Cell Therapies Market?

The increasing cases of cancer are expected to propel the growth of the allogeneic T cell therapies market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Cancer cases are rising due to factors such as longer lifespans, lifestyle changes, environmental exposures, infections, genetic factors, and changes in reproductive patterns, which collectively contribute to a higher incidence and detection of the disease. Allogeneic T cell therapies are used in cancer patients to target and kill cancer cells by infusing genetically engineered donor T cells that recognize specific tumor antigens. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, there were about 18.1 million cancer survivors in the United States. This figure is projected to rise to 22.5 million by 2032. By 2040, it's expected that the number of new cancer cases each year will reach 29.9 million, with cancer-related deaths estimated to increase to 15.3 million. Therefore, the increasing cases of cancer drive the allogeneic T cell therapies industry.

Key Players In The Global Allogeneic T Cell Therapies Market

Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.

Global Allogeneic T Cell Therapies Market Trends and Insights

Major companies operating in the allogeneic T cell therapies market are focusing on developing advanced products, such as gene-edited donor-derived CAR-T and TCR T cell therapies, to gain a competitive edge in the market. Gene-edited donor-derived T cell therapies refer to immune-effector T cells sourced from healthy donors that are genetically manipulated (e.g., knocked-out T cell receptor (TCR) and HLA genes, inserted CAR/TCR constructs, built-in safety switches) to create universal off-the-shelf products that can be manufactured in bulk, cryopreserved, and administered rapidly without patient-specific manufacture. For instance, in January 2024, Allogene Therapeutics, a US-based cell therapy company, announced its 2024 platform vision centred on ALPHA3, the industry’s first pivotal trial of an allogeneic CAR-T programme utilising gene-editing technologies to eliminate graft-versus-host disease (GvHD) risk and allow rapid donor-based delivery. The product features include donor-derived T cells edited to remove endogenous TCR and HLA molecules to reduce host immune rejection and GvHD, a chimeric antigen receptor targeting a tumour antigen enabling prompt anti-cancer activity, and cryopreserved ready-to-infuse format to shorten time to treatment compared to autologous therapies.

What Are Latest Mergers And Acquisitions In The Allogeneic T Cell Therapies Market?

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed amount. This acquisition strengthens AstraZeneca’s oncology capabilities by adding Neogene’s expertise in developing cutting-edge T-cell receptor (TCR) therapies targeting cancer-specific mutations in solid tumors. It further enhances the company’s ability to advance innovative cell-based medicines that improve outcomes for patients with hard-to-treat cancers. Neogene Therapeutics Inc. is a US-based biotechnology company that provides allogeneic T-cell therapies.

Regional Insights

North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Allogeneic T Cell Therapies Market?

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Allogeneic T Cell Therapies Market Report 2026?

The allogeneic t cell therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the allogeneic t cell therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.